1-(chloromethyl)-3-(trifluoroacetyl)-1,2-dihydro-3H-benzo[e]-indole-6-sulfonyl chloride | 885226-98-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(chloromethyl)-3-(trifluoroacetyl)-1,2-dihydro-3H-benzo[e]-indole-6-sulfonyl chloride
• 英文别名: 1-(chloromethyl)-3-(trifluoroacetyl)-1,2-dihydro-3H-benzo[e]indole-6-sulfonyl chloride；1-(chloromethyl)-3-(2,2,2-trifluoroacetyl)-1,2-dihydrobenzo[e]indole-6-sulfonyl chloride
• CAS: 885226-98-2
• 化学式: C₁₅H₁₀Cl₂F₃NO₃S
• 分子量: 412.217
• InChiKey: ROYLSPNHHNIUTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(chloromethyl)-3-(trifluoroacetyl)-1,2-dihydro-3H-benzo[e]-indole-6-sulfonyl chloride 在 硫酸 、 potassium nitrate 作用下， 反应 0.5h， 以59%的产率得到1-(chloromethyl)-5-nitro-3-(trifluoroacetyl)-1,2-dihydro-3H-benzo[e]indole-6-sulfonyl chloride
  参考文献：
  名称：

  Hypoxia-Activated Prodrugs: Substituent Effects on the Properties of Nitro seco-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) Prodrugs of DNA Minor Groove Alkylating Agents

  摘要：

  Nitrochloromethylbenzindolines (nitroCBIs) are a new class of hypoxia-activated prodrugs for antitumor therapy. The recently reported prototypes undergo hypoxia-selective metabolism to form potent DNA minor groove alkylating agents and are selectively toxic to some but not all hypoxic tumor cell lines. Here we report a series of 31 analogues that bear an extra electron-withdrawing substituent that serves to raise the one-electron reduction potential of the nitroCBI. We identify a subset of compounds, those with a basic side chain and sulfonamide or carboxamide substituent, that have consistently high hypoxic selectivity. The best of these, with a 7-sulfonamide substituent, displays hypoxic cytotoxicity ratios of 275 and 330 in Skov3 and HT29 human tumor cell lines, respectively. This compound (28) is efficiently and selectively metabolized to the corresponding aminoCBI, is selectively cytotoxic tinder hypoxia in all 11 cell lines examined, and demonstrates activity against hypoxic tumor cells in a human tumor xenograft in vivo.

  DOI：

  10.1021/jm901202b
• 作为产物：
  描述：

  tert-butyl (1-bromonaphthalen-2-yl)carbamate 在 盐酸 、 氯磺酸 、 偶氮二异丁腈 、 三正丁基氢锡 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 6.58h， 生成 1-(chloromethyl)-3-(trifluoroacetyl)-1,2-dihydro-3H-benzo[e]-indole-6-sulfonyl chloride
  参考文献：
  名称：

  具有大量抗癌活性的nitroCBI缺氧激活前药的优化合成

  摘要：

  描述了与天然产物杜卡霉素家族有关的缺氧激活的抗癌前药的优化合成方法。改进的10步合成将总收率从4.4％提高到40％以上，而仅需进行2次基于色谱的纯化。最重要的改进是在关键的氯磺酰化反应中优化了异构体的分布，并促进了从氢化三丁基锡介导的自由基反应中去除锡残留物。还报道了改进的两个侧链的制备。该新方法为获得足够的材料提供了实用途径，以支持先进的功效和毒理学评估。

  DOI：

  10.1016/j.tet.2019.04.027

文献信息

• Nitrobenzindoles and Their use in Cancer Therapy
  申请人：Denny William Alexander

  公开号：US20080119442A1

  公开（公告）日：2008-05-22

  The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及硝基-1,2-二氢-3H-苯并[e]吲哚及其相关类似物，其制备方法以及其作为低氧选择性药物和放射增敏剂在癌症治疗中的使用，可以单独使用或与辐射和/或其他抗癌药物联合使用。
• Nitrobenzindoles and their use in cancer therapy
  申请人：Auckland Uniservices Limited

  公开号：US07718688B2

  公开（公告）日：2010-05-18

  The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及硝基-1,2-二氢-3H-苯并[e]吲哚及其相关类似物，其制备方法以及它们作为治疗癌症的低氧选择性药物和放射增敏剂的用途，无论是单独使用还是与放射线和/或其他抗癌药物联合使用。
• WO2006/43839
  申请人：——

  公开号：——

  公开（公告）日：——
• US7718688B2
  申请人：——

  公开号：US7718688B2

  公开（公告）日：2010-05-18
• Hypoxia-Activated Prodrugs: Substituent Effects on the Properties of Nitro <i>seco</i>-1,2,9,9a-Tetrahydrocyclopropa[<i>c</i>]benz[<i>e</i>]indol-4-one (nitroCBI) Prodrugs of DNA Minor Groove Alkylating Agents
  作者：Moana Tercel、Graham J. Atwell、Shangjin Yang、Ralph J. Stevenson、K. Jane Botting、Maruta Boyd、Eileen Smith、Robert F. Anderson、William A. Denny、William R. Wilson、Frederik B. Pruijn

  DOI：10.1021/jm901202b

  日期：2009.11.26

  Nitrochloromethylbenzindolines (nitroCBIs) are a new class of hypoxia-activated prodrugs for antitumor therapy. The recently reported prototypes undergo hypoxia-selective metabolism to form potent DNA minor groove alkylating agents and are selectively toxic to some but not all hypoxic tumor cell lines. Here we report a series of 31 analogues that bear an extra electron-withdrawing substituent that serves to raise the one-electron reduction potential of the nitroCBI. We identify a subset of compounds, those with a basic side chain and sulfonamide or carboxamide substituent, that have consistently high hypoxic selectivity. The best of these, with a 7-sulfonamide substituent, displays hypoxic cytotoxicity ratios of 275 and 330 in Skov3 and HT29 human tumor cell lines, respectively. This compound (28) is efficiently and selectively metabolized to the corresponding aminoCBI, is selectively cytotoxic tinder hypoxia in all 11 cell lines examined, and demonstrates activity against hypoxic tumor cells in a human tumor xenograft in vivo.